CD274 and non-small cell lung carcinoma: Thus, a path forward for FNA and PEA analytics may with respect to immune‐ and oncogenic signaling analyses be assessment of samples from a larger cohort of NSCLC patients who in a metastatic setting have been given uniform PD‐1/PD‐L1‐based immune therapy.